Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma.
Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma.
复制标题
DOI：
10.3389/fonc.2023.1178966
复制
发表时间：
2023
影响因子：
4.7
通讯作者：
Pan, Weidong
中科院分区：
文献类型：
--
作者：
Peng, Wenguang;Yang, Jiarui;Xia, Long;Qian, Xiangjun;Long, Guojie;Zhang, Hao;Xie, Jiancong;Zhao, Junzhang;Zhang, Lei;Pan, Weidong
关键词：
免疫原性细胞死亡（ICD）是一种足以引发适应性免疫反应的调节性细胞死亡（RCD）。根据目前的研究结果，ICD有能力通过产生危险信号或损伤相关分子模式（DAMP）来改变肿瘤免疫微环境，这可能有助于免疫治疗。开发ICD相关的生物标志物将是有益的，这些生物标志物根据个体对ICD免疫治疗的反应程度对个体进行分类。我们使用共识聚类来确定两个ICD相关分组。ICD高亚型与良好的临床结局、显著的免疫细胞浸润和强大的免疫应答信号传导活性相关。此外，我们开发并验证了基于肿瘤免疫微环境的ICD相关PDAC生存预后模型。我们还收集了48例PDAC患者的临床和病理资料，EIF2A高表达的患者预后不良。最后，基于ICD签名，我们开发了一种新的PDAC分类方法。这种分类对确定预后和免疫治疗具有重要的临床意义。我们的工作强调了ICD亚型变异与PDAC中免疫肿瘤微环境改变之间的联系。这些发现可能有助于PDAC患者的免疫治疗。我们还创建并验证了ICD相关的预后特征，这对估计患者的总生存时间（OS）有重大影响。
Immunogenic cell death (ICD) is a sort of regulated cell death (RCD) sufficient to trigger an adaptive immunological response. According to the current findings, ICD has the capacity to alter the tumor immune microenvironment by generating danger signals or damage-associated molecular patterns (DAMPs), which may contribute in immunotherapy. It would be beneficial to develop ICD-related biomarkers that classify individuals depending on how well they respond to ICD immunotherapy. We used consensus clustering to identify two ICD-related groupings. The ICD-high subtype was associated with favorable clinical outcomes, significant immune cell infiltration, and powerful immune response signaling activity. In addition, we developed and validated an ICD-related prognostic model for PDAC survival based on the tumor immune microenvironment. We also collected clinical and pathological data from 48 patients with PDAC, and patients with high EIF2A expression had a poor prognosis. Finally, based on ICD signatures, we developed a novel PDAC categorization method. This categorization had significant clinical implications for determining prognosis and immunotherapy. Our work emphasizes the connections between ICD subtype variations and alterations in the immune tumor microenvironment in PDAC. These findings may help the immune therapy-based therapies for patients with PDAC. We also created and validated an ICD-related prognostic signature, which had a substantial impact on estimating patients' overall survival times (OS).
登录
查看更多内容
影响因子：
--
作者：
Ribatti D
通讯作者：
Ribatti D
通过肿瘤微环境调节智能纳米囊泡介导的免疫原性细胞死亡，实现有效的光动力免疫治疗
影响因子：
17.1
作者：
Yang, Weijing;Zhang, Fuwu;Chen, Xiaoyuan
通讯作者：
Chen, Xiaoyuan
影响因子：
9
作者：
Qin J;Kunda N;Qiao G;Calata JF;Pardiwala K;Prabhakar BS;Maker AV
通讯作者：
Maker AV
影响因子：
37.3
作者：
Ren B;Cui M;Yang G;Wang H;Feng M;You L;Zhao Y
通讯作者：
Zhao Y
DOI：
10.1007/978-3-319-39406-0_6
发表时间：
2016-01-01
期刊：
APOPTOSIS IN CANCER PATHOGENESIS AND ANTI-CANCER THERAPY: NEW PERSPECTIVES AND OPPORTUNITIES
影响因子：
--
作者：
Vandenabeele, Peter;Vandecasteele, Katrien;Krysko, Dmitri V.
通讯作者：
Krysko, Dmitri V.